Residual microcalcifications after neoadjuvant systemic therapy for early breast cancer: Implications for surgical planning and long-term outcomes

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso Pub Date : 2024-10-22 DOI:10.1016/j.ejso.2024.108781

Joel Allotey , Vinita Ruparel , Anna McCallum , Karendeep Somal , Louise Simpson , Gaurav Gupta , Gerald Lip , Ravi Sharma , Yazan Masannat

{"title":"Residual microcalcifications after neoadjuvant systemic therapy for early breast cancer: Implications for surgical planning and long-term outcomes","authors":"Joel Allotey , Vinita Ruparel , Anna McCallum , Karendeep Somal , Louise Simpson , Gaurav Gupta , Gerald Lip , Ravi Sharma , Yazan Masannat","doi":"10.1016/j.ejso.2024.108781","DOIUrl":null,"url":null,"abstract":"<div><div>Residual microcalcifications on mammograms after neoadjuvant chemotherapy (NACT) pose a challenge in surgical decision-making. This single-centre retrospective review of all patients who had NACT for breast cancer over five years, evaluated the relationship between pathological complete response and residual microcalcifications, controlling for tumour size, nodal stage, grade, and receptor status, as well as the impact of residual microcalcifications on recurrence and survival. There was no significant association between pathological complete response (pCR) and residual microcalcifications (p = 0.763). We computed hazard ratios (HR) for Time to recurrence (TTR) and overall survival (OS) which were both not significant, with HR = 2.599, [0.290, 23.264], p = 0.393 and HR = 1.362 [0.123, 15.062], p = 0.801 respectively. The predictive and prognostic significance of residual microcalcifications remains to be proven. The surgical excision of these lesions should be considered based on individual patient risk.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 1","pages":"Article 108781"},"PeriodicalIF":3.5000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejso","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0748798324008497","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Residual microcalcifications on mammograms after neoadjuvant chemotherapy (NACT) pose a challenge in surgical decision-making. This single-centre retrospective review of all patients who had NACT for breast cancer over five years, evaluated the relationship between pathological complete response and residual microcalcifications, controlling for tumour size, nodal stage, grade, and receptor status, as well as the impact of residual microcalcifications on recurrence and survival. There was no significant association between pathological complete response (pCR) and residual microcalcifications (p = 0.763). We computed hazard ratios (HR) for Time to recurrence (TTR) and overall survival (OS) which were both not significant, with HR = 2.599, [0.290, 23.264], p = 0.393 and HR = 1.362 [0.123, 15.062], p = 0.801 respectively. The predictive and prognostic significance of residual microcalcifications remains to be proven. The surgical excision of these lesions should be considered based on individual patient risk.

查看原文本刊更多论文

早期乳腺癌新辅助系统治疗后的残留微钙化：对手术规划和长期疗效的影响

新辅助化疗（NACT）后乳房X光片上残留的微小钙化给手术决策带来了挑战。这项单中心回顾性研究对五年来所有接受新辅助化疗的乳腺癌患者进行了评估，在控制肿瘤大小、结节分期、分级和受体状态的情况下，评估了病理完全反应与残留微小钙化之间的关系，以及残留微小钙化对复发和生存的影响。病理完全反应（pCR）与残留微小钙化之间无明显关联（p = 0.763）。我们计算了复发时间（TTR）和总生存率（OS）的危险比（HR），结果均不显著，分别为 HR = 2.599 [0.290, 23.264], p = 0.393 和 HR = 1.362 [0.123, 15.062], p = 0.801。残留微钙化的预测和预后意义仍有待证实。应根据患者的个体风险考虑手术切除这些病灶。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ejso 医学-外科

CiteScore

6.40

自引率

2.60%

发文量

1148

审稿时长

41 days

期刊介绍： JSO - European Journal of Surgical Oncology ("the Journal of Cancer Surgery") is the Official Journal of the European Society of Surgical Oncology and BASO ~ the Association for Cancer Surgery. The EJSO aims to advance surgical oncology research and practice through the publication of original research articles, review articles, editorials, debates and correspondence.